http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 20 Aug 2026 18:23:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26957382.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on <chron>August 20, 2026</chron> under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26957382.html Thu, 20 Aug 2026 18:23:00 -0400 A.50217003 O.76946938 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26957382.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on <chron>August 20, 2026</chron> under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26957382.html Thu, 20 Aug 2026 18:23:00 -0400 A.50217003 O.76946938 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26957382.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on <chron>August 20, 2026</chron> under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26957382.html Thu, 20 Aug 2026 18:23:00 -0400 A.50217003 O.76946938 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26957382.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on <chron>August 20, 2026</chron> under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26957382.html Thu, 20 Aug 2026 18:23:00 -0400 A.50217003 O.76946938 RNA RNA http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26957382.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on <chron>August 20, 2026</chron> under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26957382.html Thu, 20 Aug 2026 18:23:00 -0400 A.50217003 O.76946938 RNA RNA http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26957382.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on <chron>August 20, 2026</chron> under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26957382.html Thu, 20 Aug 2026 18:23:00 -0400 A.50217003 O.76946938 RNA RNA http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26957382.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on <chron>August 20, 2026</chron> under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26957382.html Thu, 20 Aug 2026 18:23:00 -0400 A.50217003 O.76946938 RNA RNA http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26957382.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on <chron>August 20, 2026</chron> under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26957382.html Thu, 20 Aug 2026 18:23:00 -0400 A.50217003 O.76946938 RNA RNA http://www.streetinsider.com/Earnings/Prosensa+Holding+N.V.+%28RNA%29+Reports+Q2+Loss+of+%241.18/26923622.html <p>Prosensa Holding N.V. (NASDAQ: RNA) reported Q2 EPS of ($1.18).</p><p>For earnings history and earnings-related data on Prosensa Holding N.V. (RNA) <a href="http://www.streetinsider.com/ec_earnings.php?q=RNA">click here</a>.</p> http://www.streetinsider.com/Earnings/Prosensa+Holding+N.V.+%28RNA%29+Reports+Q2+Loss+of+%241.18/26923622.html Fri, 14 Aug 2026 05:47:48 -0400 RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html <div class="xn-content"> <p class="prntac"><i>-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in </i><i>PRKAG2 syndrome --</i></p><p class="prntac"><i>-- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "<span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics</span>," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended <chron>June 30, 2026</chron>, and highlighted recent corporate progress including <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> clearance of its Investigational New Drug (IND) application for ATR 1072 http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html Thu, 13 Aug 2026 16:44:00 -0400 A.06822034 A.17150087 A.31691663 A.50114146 A.50217003 O.08045350 O.15127974 O.20026344 O.34929518 O.76946938 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html <div class="xn-content"> <p class="prntac"><i>-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in </i><i>PRKAG2 syndrome --</i></p><p class="prntac"><i>-- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "<span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics</span>," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended <chron>June 30, 2026</chron>, and highlighted recent corporate progress including <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> clearance of its Investigational New Drug (IND) application for ATR 1072 http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html Thu, 13 Aug 2026 16:44:00 -0400 A.06822034 A.17150087 A.31691663 A.50114146 A.50217003 O.08045350 O.15127974 O.20026344 O.34929518 O.76946938 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html <div class="xn-content"> <p class="prntac"><i>-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in </i><i>PRKAG2 syndrome --</i></p><p class="prntac"><i>-- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "<span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics</span>," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended <chron>June 30, 2026</chron>, and highlighted recent corporate progress including <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> clearance of its Investigational New Drug (IND) application for ATR 1072 http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html Thu, 13 Aug 2026 16:44:00 -0400 A.06822034 A.17150087 A.31691663 A.50114146 A.50217003 O.08045350 O.15127974 O.20026344 O.34929518 O.76946938 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html <div class="xn-content"> <p class="prntac"><i>-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in </i><i>PRKAG2 syndrome --</i></p><p class="prntac"><i>-- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "<span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics</span>," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended <chron>June 30, 2026</chron>, and highlighted recent corporate progress including <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> clearance of its Investigational New Drug (IND) application for ATR 1072 http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html Thu, 13 Aug 2026 16:44:00 -0400 A.06822034 A.17150087 A.31691663 A.50114146 A.50217003 O.08045350 O.15127974 O.20026344 O.34929518 O.76946938 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html <div class="xn-content"> <p class="prntac"><i>-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in </i><i>PRKAG2 syndrome --</i></p><p class="prntac"><i>-- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "<span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics</span>," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended <chron>June 30, 2026</chron>, and highlighted recent corporate progress including <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> clearance of its Investigational New Drug (IND) application for ATR 1072 http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html Thu, 13 Aug 2026 16:44:00 -0400 A.06822034 A.17150087 A.31691663 A.50114146 A.50217003 O.08045350 O.15127974 O.20026344 O.34929518 O.76946938 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html <div class="xn-content"> <p class="prntac"><i>-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in </i><i>PRKAG2 syndrome --</i></p><p class="prntac"><i>-- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "<span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics</span>," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended <chron>June 30, 2026</chron>, and highlighted recent corporate progress including <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> clearance of its Investigational New Drug (IND) application for ATR 1072 http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html Thu, 13 Aug 2026 16:44:00 -0400 A.06822034 A.17150087 A.31691663 A.50114146 A.50217003 O.08045350 O.15127974 O.20026344 O.34929518 O.76946938 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html <div class="xn-content"> <p class="prntac"><i>-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in </i><i>PRKAG2 syndrome --</i></p><p class="prntac"><i>-- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "<span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics</span>," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended <chron>June 30, 2026</chron>, and highlighted recent corporate progress including <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> clearance of its Investigational New Drug (IND) application for ATR 1072 http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html Thu, 13 Aug 2026 16:44:00 -0400 A.06822034 A.17150087 A.31691663 A.50114146 A.50217003 O.08045350 O.15127974 O.20026344 O.34929518 O.76946938 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html <div class="xn-content"> <p class="prntac"><i>-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in </i><i>PRKAG2 syndrome --</i></p><p class="prntac"><i>-- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "<span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics</span>," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended <chron>June 30, 2026</chron>, and highlighted recent corporate progress including <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> clearance of its Investigational New Drug (IND) application for ATR 1072 http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html Thu, 13 Aug 2026 16:44:00 -0400 A.06822034 A.17150087 A.31691663 A.50114146 A.50217003 O.08045350 O.15127974 O.20026344 O.34929518 O.76946938 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html <div class="xn-content"> <p class="prntac"><i>-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in </i><i>PRKAG2 syndrome --</i></p><p class="prntac"><i>-- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "<span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics</span>," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended <chron>June 30, 2026</chron>, and highlighted recent corporate progress including <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> clearance of its Investigational New Drug (IND) application for ATR 1072 http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html Thu, 13 Aug 2026 16:44:00 -0400 A.06822034 A.17150087 A.31691663 A.50114146 A.50217003 O.08045350 O.15127974 O.20026344 O.34929518 O.76946938 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html <div class="xn-content"> <p class="prntac"><i>-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in </i><i>PRKAG2 syndrome --</i></p><p class="prntac"><i>-- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "<span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics</span>," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended <chron>June 30, 2026</chron>, and highlighted recent corporate progress including <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> clearance of its Investigational New Drug (IND) application for ATR 1072 http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html Thu, 13 Aug 2026 16:44:00 -0400 A.06822034 A.17150087 A.31691663 A.50114146 A.50217003 O.08045350 O.15127974 O.20026344 O.34929518 O.76946938 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html <div class="xn-content"> <p class="prntac"><i>-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in </i><i>PRKAG2 syndrome --</i></p><p class="prntac"><i>-- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "<span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics</span>," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended <chron>June 30, 2026</chron>, and highlighted recent corporate progress including <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> clearance of its Investigational New Drug (IND) application for ATR 1072 http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html Thu, 13 Aug 2026 16:44:00 -0400 A.06822034 A.17150087 A.31691663 A.50114146 A.50217003 O.08045350 O.15127974 O.20026344 O.34929518 O.76946938 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html <div class="xn-content"> <p class="prntac"><i>-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in </i><i>PRKAG2 syndrome --</i></p><p class="prntac"><i>-- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "<span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics</span>," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended <chron>June 30, 2026</chron>, and highlighted recent corporate progress including <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> clearance of its Investigational New Drug (IND) application for ATR 1072 http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html Thu, 13 Aug 2026 16:44:00 -0400 A.06822034 A.17150087 A.31691663 A.50114146 A.50217003 O.08045350 O.15127974 O.20026344 O.34929518 O.76946938 RNA RNA http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html <div class="xn-content"> <p class="prntac"><i>-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in </i><i>PRKAG2 syndrome --</i></p><p class="prntac"><i>-- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "<span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics</span>," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended <chron>June 30, 2026</chron>, and highlighted recent corporate progress including <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> clearance of its Investigational New Drug (IND) application for ATR 1072 http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html Thu, 13 Aug 2026 16:44:00 -0400 A.06822034 A.17150087 A.31691663 A.50114146 A.50217003 O.08045350 O.15127974 O.20026344 O.34929518 O.76946938 RNA RNA http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html <div class="xn-content"> <p class="prntac"><i>-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in </i><i>PRKAG2 syndrome --</i></p><p class="prntac"><i>-- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "<span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics</span>," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended <chron>June 30, 2026</chron>, and highlighted recent corporate progress including <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> clearance of its Investigational New Drug (IND) application for ATR 1072 http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html Thu, 13 Aug 2026 16:44:00 -0400 A.06822034 A.17150087 A.31691663 A.50114146 A.50217003 O.08045350 O.15127974 O.20026344 O.34929518 O.76946938 RNA RNA http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html <div class="xn-content"> <p class="prntac"><i>-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in </i><i>PRKAG2 syndrome --</i></p><p class="prntac"><i>-- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "<span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics</span>," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended <chron>June 30, 2026</chron>, and highlighted recent corporate progress including <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> clearance of its Investigational New Drug (IND) application for ATR 1072 http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html Thu, 13 Aug 2026 16:44:00 -0400 A.06822034 A.17150087 A.31691663 A.50114146 A.50217003 O.08045350 O.15127974 O.20026344 O.34929518 O.76946938 RNA RNA http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html <div class="xn-content"> <p class="prntac"><i>-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in </i><i>PRKAG2 syndrome --</i></p><p class="prntac"><i>-- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "<span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics</span>," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended <chron>June 30, 2026</chron>, and highlighted recent corporate progress including <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> clearance of its Investigational New Drug (IND) application for ATR 1072 http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26922285.html Thu, 13 Aug 2026 16:44:00 -0400 A.06822034 A.17150087 A.31691663 A.50114146 A.50217003 O.08045350 O.15127974 O.20026344 O.34929518 O.76946938 RNA RNA